Back to Agenda
Session 4 : Panel Discussion : PV and Covid, Expectations vs Reality
Session Chair(s)
Ritu Jaswal
Vice President- Pharmacovigilance Operations
PAREXEL, India
In this Session we will reflect on how we expected the Covid drugs / vaccines to sell and geared ourselves for related PV WORK and the reality.
CROs/pharma companies were going through extensive communication at each step for preparation and alignment of all stakeholders. The organizations also invested heavily in PV training in different units to handle anticipated vaccine volumes. As the pandemic curve started a downward trend, the PV work eventually started declining and there were staff adjustments. The reasons probably were decline in the Covid severity, rapidly changing variants, public herd immunity, reduced restrictions on mandatory vaccination, etc.
The discussion will focus on the related expectations in the beginning of vaccines being launched and how this slowly unfolded for PV over time with the evolution of pandemic.
Speaker(s)
Contributing Panelist
Renu Sharma
Parexel, India
Senior Director Pharmacovigilance Operations
Contributing Panelist
Geethashree Shambu
Indegene Pvt Ltd, India
Delivery Lead - Safety Operations
Contributing Panelist
Chetanraj Bhamare
and pharmacovigilance dept., Serum Institute of India Pvt Ltd, India
Safety Physician (Asst. General Manager), Clinical research
Contributing Panelist
Jamal Anwar Baig, PhD
Sanofi, India
Multi Country Safety Head – South Asia & Indo-China (Vietnam)
Have an account?